ALEPH-FARMS
8.12.2021 12:11:09 CET | Business Wire | Press release
Aleph Farms , the first cultivated meat company to grow steaks directly from non-genetically engineered animal cells and WACKER , a supplier of leading protein production technologies, today announced the development of streamlined production processes for essential growth medium proteins to cost-effectively grow cultivated meat. These proteins, central to promoting and supporting cell growth, are not widely available in the market today and represent one of the most prohibitive expenses in scaling up cultivated meat. The agreement between WACKER and Aleph Farms is non-exclusive, meaning any cultivated meat company will be able to obtain these same affordable proteins, without using fetal bovine serum (FBS) or animal-derived ingredients. This open supply chain solution is expected to enable the industry to scale and achieve price-parity faster, eliminating a key hurdle in the commercial viability of cultivated meat.
"Bringing down the cost and making suitable raw materials available at this key moment in the scale-up of production is imperative to taking cultivated meat mainstream and driving impact”, said Didier Toubia, Co-Founder and CEO of Aleph Farms. "Investing in the development of a supply chain solution available to the entire industry is a direct result of our innovative and inclusive business model and the impetus behind our partnership with WACKER.”
WACKER brings over 20 years of experience in protein production to the partnership, as well as a deep understanding of the food industry’s requirements and regulations. At its corporate research labs in Munich, WACKER is working on fermentation techniques for producing cell culture proteins for use in food applications, which will have the same composition of proteins produced inside the animal’s body. Similar production techniques are widely used today to produce enzymes for food processing applications.
“The market for cultivated meat is advancing rapidly and we want to contribute to making it an affordable reality for everyone,” said Susanne Leonhartsberger, president of WACKER BIOSOLUTIONS, WACKER´s life science division. “At WACKER, we have many years of experience in the field of protein production. Our scientists have developed advanced production technologies that we can draw on. With this platform, we are now entering the field of cultivated meat. As the most technologically advanced company in the field, Aleph Farms is an ideal partner for us in this project.”
“Our team’s scientific expertise alongside WACKER’s vast experience makes it possible to produce proteins at the quantity, quality and cost necessary to meet Aleph’s aggressive goal of achieving cost-parity with conventional meat.", said Ayelet Maor Shoshani Ph.D., Director of Cell Line and Media Development at Aleph Farms.
Growth-medium proteins are essential components naturally found in animals and today represent the main cost drivers of cultivated meat production. They act as a nutrient-rich feed to help cells grow and mature into muscle, fat and collagen-producing cells and are imperative for supporting cellular activity. The aim is for this partnership to realize a significant reduction in the cost of these proteins by matching the standard of quality and scale to the food industry. The proteins are to be made available to all cultivated meat companies in the industry.
About WACKER BIOSOLUTIONS
Using advanced biotech processes, WACKER BIOSOLUTIONS provides tailored, innovative solutions and products to the life-sciences sector – including pharmaceutical proteins, cyclodextrins and fermentation-generated cysteine. The portfolio is additionally complemented with catalog chemicals such as acetylacetone. The division focuses on developing customized solutions for growth sectors, such as food ingredients, pharmaceutical activities and agrochemicals. WACKER BIOSOLUTIONS is the life science division of the Munich based WACKER group. For more information visit www.wacker.com
About Aleph Farms
Aleph Farms grows beef steaks, from non-genetically engineered and non-immortalized cells isolated from a living cow, without slaughtering the animal and with a significantly reduced impact to the environment. The company’s vision is to provide unconditional quality nutrition for anyone, anytime, anywhere. For more information, follow Aleph Farms on Instagram , Twitter , Facebook or LinkedIn or visit www.aleph-farms.com . Access the Aleph Farms press kit here .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211208005501/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Darktrace Selects Navan to Modernise Travel Program25.2.2026 10:00:00 CET | Press release
Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced it has been selected by Darktrace, a global leader in AI for cybersecurity, to upgrade its global travel program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260225522665/en/ Darktrace Selects Navan to Modernise Travel Program “As Darktrace accelerates its expansion, in-person collaboration is critical,” said David Smith, Chief People Officer at Darktrace. “Navan’s inventory and user experience will ensure our teams and customers can easily connect, while we can maintain financial control.” As the UK-based cybersecurity company grows, Darktrace sought a partner to consolidate its travel operations, minimize administrative burden, and improve the booking experience for its workforce. Previously hampered by fragmented processes, Darktrace required a solution that would increase platform adoption and empower its employees to tra
AI: The New Insider Threat Facing Organizations25.2.2026 09:00:00 CET | Press release
Thales 2026 Data Threat Report Finds 70% of Organizations Rank AI as Top Data Security Risk As AI systems gain broader access to enterprise data across environments, organizations must treat data visibility and encryption as core security elements. AI-enabled deepfakes and misinformation are increasing the effectiveness of identity-based attacks. Today, credential theft is the leading attack technique against cloud infrastructure (67%). Nearly 60% of companies report deepfake-driven incidents, and 48% experience damage from AI-generated misinformation Investment in AI security is growing, with 30% of companies allocating dedicated budgets; however, 53% are still relying on existing security budget According to the Thales 2026 Data Threat Report, organizations across various markets including automotive, energy, finance and retail say the rapid pace of AI-driven transformation is now their biggest security challenge. Based on the report’s research, conducted by S&P Global 451 Research,
Zuper and Vonage Reimagine Network Connectivity for Skilled Trades with Quality on Demand25.2.2026 09:00:00 CET | Press release
Zuper to receive early access to Vonage Quality on Demand network API, for high-stakes field workflows - ensuring reliable network performance for live video, wearables, and inspections across industries like HVAC, electrical, general construction, roofing, manufacturing, and more Zuper, the AI operating system for the trades, and Vonage, part of Ericsson, have entered into a Memorandum of Understanding (MoU) to enter into a collaboration to integrate Vonage’s network APIs into the Zuper platform. The collaboration will provide Zuper with early access to Vonage network powered solutions, starting with Quality on Demand (QoD), where mobile network performance can be selectively applied to support critical field workflows, delivering improved latency, reliability, and connected experiences for mobile workforces. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260225852261/en/ QoD is the first advanced network API being integrat
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 08:07:00 CET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 08:00:00 CET | Press release
CE Marking enables marketing and clinical use of the world’s first and only LINAC vault-ready proton therapy system across the European Union Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom